glp 1 agonist history Discovery of GLP-1–Based Drugs for the Treatment of Obesity Addressing patient concerns about the
Description
In July 2024 , Genentech , a member of the Roche Group announced positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity
Written by Dr
each has a different mechanism of action to achieve the same result
2011;343:d5928
